Distribution Halted for Ranitidine (Generic for Zantac)
Distribution has been halted for generic Ranitidine after an announcement that the US Food and Drug Administration (FDA) is investigating medications containing ranitidine that may have a possible link to cancer.
This generic medication is taken by millions to help with gastrointestinal disorders and discomfort. The manufacturer stated that this is a “precautionary distribution stop” as they complete an internal investigation and the FDA continues its own research to determine if the low levels of the ingredient pose a risk to patients.
If you or a family member has been prescribed this generic medication, here are some key points to know about this issue:
Brand-name Zantac is not included in the distribution halt. Those currently on the generic version can purchase the brand-name over-the-counter medication.
Pediatric patients on liquid ranitidine do not need to switch. The halt only involves the capsule/tablet version
is currently a distribution halt, not a recall. The manufacturer is taking precautionary measures as investigations continue and more information will be released as it becomes available.